USO 20345
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAIVE PATIENTS WITH MYELOFIBROSIS (XPORT-MF-034)
Disease Types: Hematology
Eligibility Requirements:
• Diagnosis of primary myelofibrosis, post-ET, or post PV
myelofibrosis according to 2016 WHO
• Spleen must be enlarged, measuring 450 cm³ or more,
as shown by an MRI or CT scan during screening
• Subject cannot be eligible for stem cell transplantation
• ECOG ≤ 2
• Subjects with more than 10% blasts in peripheral blood or
bone marrow are excluded
• Subjects that have received treatment with JAK inhibitors
are excluded
• Subjects must have DIPSS risk category of intermediate1, or intermediate-2, or high-risk
For more information on this trial CLICK HERE .
Available at: